Immunogenicity and safety after booster vaccination of diphtheria, tetanus, and acellular pertussis in young adults: An open randomized controlled trial in Japan

Clinical and Vaccine Immunology

Volumn 20, Issue 12, 2013, Pages 1799-1804

  Hara, Megumi ^a   Okada, Kenji ^b   Yamaguchi, Yuko ^c   Uno, Shingo ^c   Otsuka, Yasuko ^a   Shimanoe, Chisato ^a   Nanri, Hinako ^a   Horita, Mikako ^a   Ozaki, Iwata ^d   Nishida, Yuichiro ^a   Tanaka, Keitaro ^a  

^a SAGA UNIVERSITY   (Japan)

^b FUKUOKA DENTAL COLLEGE   (Japan)

^c Kaketsuken   (Japan)

^d SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; HEMAGGLUTININ; PERTUSSIS TOXIN; TETANUS TOXOID;

ADULT; ANTIBODY DETECTION; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COUGHING; DIPHTHERIA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHASIA; DYSPNEA; ERYTHEMA; FACE EDEMA; FATIGUE; FEMALE; FEVER; HOARSENESS; HUMAN; HYPEREMIA; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOASSAY; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE WARMTH; JAPAN; MALE; OUTCOME ASSESSMENT; PAIN; PERTUSSIS; PRIORITY JOURNAL; PRURITUS; SINGLE DRUG DOSE; SKIN REDNESS; SORE THROAT; SWELLING; TETANUS;

ADULT; ANTIBODIES, BACTERIAL; DIPHTHERIA; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOASSAY; JAPAN; MALE; SEROLOGIC TESTS; TETANUS; VACCINATION; VACCINES, ACELLULAR; WHOOPING COUGH; YOUNG ADULT;

EID: 84888600617     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00490-13     Document Type: Article

References (29)

1. Zepp F, Heininger U, Mertsola J, Bernatowska E, Guiso N, Roord J, Tozzi AE, Van Damme P. 2011. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect. Dis. 11:557-570.
2. Cherry JD. 2010. The present and future control of pertussis. Clin. Infect. Dis. 51:663-667.
3. Cherry JD. 2012. Epidemic pertussis in 2012-the resurgence of a vaccine-preventable disease. N. Engl. J. Med. 367:785-787.
4. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. 2005. Duration of immunity against pertussis after natural infection or vaccination. Pediatr. Infect. Dis. J. 24:S58-S61.
5. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. 2012. Waning protection after fifth dose of acellular pertussis vaccine in children. N. Engl. J. Med. 367:1012-1019.
6. Han HJ, Kamachi K, Okada K, Toyoizumi-Ajisaka H, Sasaki Y, Arakawa Y. 2008. Antigenic variation in Bordetella pertussis isolates recovered from adults and children in Japan. Vaccine 26:1530-1534.
7. Kamano H, Mori T, Maeta H, Taminato T, Ishida T, Kishimoto N, Katami T, Sato M, Kamachi K, Mochida Y. 2010. Analysis of Bordetella pertussis agglutinin titers during an outbreak of pertussis at a university in Japan. Jpn. J. Infect. Dis. 63:108-112.
8. Miyashita N, Kawai Y, Yamaguchi T, Ouchi K, Kurose K, Oka M. 2011. Outbreak of pertussis in a university laboratory. Intern. Med. 50:879-885.
9. Otsuka N, Han HJ, Toyoizumi-Ajisaka H, Nakamura Y, Arakawa Y, Shibayama K, Kamachi K. 2012. Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan. PLoS One 7:e31985. doi:10.1371/journal.pone.0031985.
10. Kamiya H, Otsuka N, Ando Y, Odaira F, Yoshino S, Kawano K, Takahashi H, Nishida T, Hidaka Y, Toyoizumi-Ajisaka H, Shibayama K, Kamachi K, Sunagawa T, Taniguchi K, Okabe N. 2012. Transmission of Bordetella holmesii during pertussis outbreak, Japan. Emerg. Infect. Dis. 18:1166-1169.
11. Bechini A, Tiscione E, Boccalini S, Levi M, Bonanni P. 2012. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations. Vaccine 30:5179-5190.
12. Food and Drug Administration. 2005. Adacel, Sanofi Pasteur (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed), full prescribing information. U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/ biologicsbloodvaccines/vaccines/approvedproducts/ucm142764.pdf.
13. Food and Drug Administration. 2011. Boostrix, GlaxoSmithKline Biologicals (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis Vaccine, adsorbed), highlights of prescribing information. U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/biologicsbloodvaccines/ucm152842.pdf.
14. Okada K, Komiya T, Yamamoto A, Takahashi M, Kamachi K, Nakano T, Nagai T, Okabe N, Kamiya H, Nakayama T. 2010. Safe and effective booster immunization using DTaP in teenagers. Vaccine 28:7626-7633.
15. Sato Y, Kimura M, Fukumi H. 1984. Development of a pertussis component vaccine in Japan. Lancet i:122-126.
16. Miyamura K, Nishio S, Ito A, Murata R, Kono R. 1974. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. I. Studies on factors affecting the toxin and antitoxin titration. J. Biol. Stand. 2:189-201.
17. Coplu N, Esen B, Gozalan A, Miyamura K, Yoshida I, Kurtoglu D, Dogan NO, Afacan G, Unal A, Ishida S, Takahashi M. 2004. Tetanus antibody assay combining in-house ELISA and particle agglutination test and its serosurvey application in a province in Turkey. Jpn. J. Infect. Dis. 57:97-102.
18. Blatter M, Friedland LR, Weston WM, Li P, Howe B. 2009. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine 27:765-772.
19. Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, Giammanco A. 2001. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 108:E81.
20. Olin P, Gustafsson L, Barreto L, Hessel L, Mast TC, Rie AV, Bogaerts H, Storsaeter J. 2003. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 21:2015-2021.
21. Mertsola J, Van Der Meeren O, He Q, Linko-Parvinen A, Ramakrishnan G, Mannermaa L, Soila M, Pulkkinen M, Jacquet JM. 2010. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin. Infect. Dis. 51:656-662.
22. Knuf M, Habermehl P, Faber J, Bock HL, Sanger R, Bogaerts H, Clemens R, Schuind A, du Prel JB, Schmitt HJ. 2006. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life. Vaccine 24:5627-5636.
23. Hendrikx LH, Berbers GA, Veenhoven RH, Sanders EA, Buisman AM. 2009. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content. Vaccine 27:6530-6536.
24. Edelman K, He Q, Makinen J, Sahlberg A, Haanpera M, Schuerman L, Wolter J, Mertsola J. 2007. Immunity to pertussis 5 years after booster immunization during adolescence. Clin. Infect. Dis. 44:1271-1277.
25. Centers for Disease Control and Prevention. 2006. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 55:1-34.
26. Centers for Disease Control and Prevention. 2006. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm. Rep. 55:1-37.
27. Centers for Disease Control and Prevention. 2011. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb. Mortal. Wkly. Rep. 60:13-15.
28. Centers for Disease Control and Prevention. 2012. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older-Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep. 61:468-470.
29. Poland GA. 2012. Pertussis outbreaks and pertussis vaccines: new insights, new concerns, new recommendations? Vaccine 30:6957-6959.